Mirae Asset Global Investments Co., Ltd. Vir Biotechnology, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

  • $20 Billion
  • Q2 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,062 shares of VIR stock, worth $31,683. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,062
Previous 49,525 91.8%
Holding current value
$31,683
Previous $501,000 92.81%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024
SELL
$7.63 - $12.66 $346,882 - $575,561
-45,463 Reduced 91.8%
4,062 $36,000
Q1 2024

May 01, 2024
SELL
$8.6 - $11.9 $1.41 Million - $1.94 Million
-163,377 Reduced 76.74%
49,525 $501,000
Q4 2023

Jan 24, 2024
BUY
$7.76 - $10.29 $1.2 Million - $1.6 Million
155,196 Added 268.94%
212,902 $2.14 Million
Q3 2023

Oct 26, 2023
BUY
$9.14 - $24.62 $33,159 - $89,321
3,628 Added 6.71%
57,706 $540,000
Q2 2023

Aug 10, 2023
BUY
$23.2 - $27.29 $107,578 - $126,543
4,637 Added 9.38%
54,078 $1.33 Million
Q1 2023

May 04, 2023
BUY
$22.26 - $30.85 $232,372 - $322,043
10,439 Added 26.77%
49,441 $1.15 Million
Q4 2022

Feb 09, 2023
BUY
$19.96 - $28.22 $47,804 - $67,586
2,395 Added 6.54%
39,002 $987,000
Q3 2022

Nov 10, 2022
SELL
$18.26 - $31.1 $1.39 Million - $2.36 Million
-75,917 Reduced 67.47%
36,607 $706,000
Q2 2022

Jul 26, 2022
BUY
$19.08 - $26.7 $2.07 Million - $2.89 Million
108,255 Added 2535.84%
112,524 $8.21 Million
Q2 2021

Aug 11, 2021
BUY
$38.75 - $51.0 $165,423 - $217,719
4,269 New
4,269 $202,000

Others Institutions Holding VIR

# of Institutions
233
Shares Held
87.6M
Call Options Held
231K
Put Options Held
132K
View Full List

About Vir Biotechnology, Inc.

VIR Quotes by TradingView
  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.03B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email